[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$foHNI9DHc1hqSa9_H8eQjENOMER0z_DRYgzR8DZnsyOo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":32,"phaseBuckets":53,"rows":60},"Dr. Falk Pharma GmbH",[4],39,false,4,24,8945,0,[13,16,19,21,23,26,28,30],{"name":14,"count":15},"Eosinophilic Esophagitis",5,{"name":17,"count":18},"Primary Sclerosing Cholangitis",3,{"name":20,"count":18},"Colitis, Ulcerative",{"name":22,"count":18},"Ulcerative Colitis",{"name":24,"count":25},"Crohn´s Disease",2,{"name":27,"count":25},"Crohn's Disease",{"name":29,"count":25},"Primary Biliary Cirrhosis",{"name":31,"count":25},"Diverticulitis",[33,38,43,48],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT03872921","norUrsodeoxycholic Acid vs Placebo in PSC","2025-01","norUrsodeoxycholic Acid",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06596252","Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE","2026-12","Budesonide",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT07298343","Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease","2027-08","ZED1227 + SIGE",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06886360","Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)","2027-09","norucholic acid",[54,55,56,57,58,59],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[61,200,234,255,276,308,375,414,450,478,496,514,540,558,585,603,621,639,657,675,700,726,749,773,800,818,836,854,880,905,923,941,967,985,1003,1028,1046,1064],{"intervention":42,"totalTrials":62,"cells":63},12,{"EARLY_PHASE1":64,"PHASE1":66,"PHASE2":68,"PHASE3":93,"PHASE4":196,"NA":198},{"trials":65,"activeCount":11},[],{"trials":67,"activeCount":11},[],{"trials":69,"activeCount":11},[70,80],{"nctId":71,"briefTitle":72,"status":73,"phases":74,"primaryCompletion":75,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":79},"NCT02550418","Budesonide 9 mg Capsules in Active UC","COMPLETED",[56],"2017-03","2015-10",60,[20],[42],{"nctId":81,"briefTitle":82,"status":83,"phases":84,"primaryCompletion":85,"completion":86,"start":87,"enrollment":88,"conditions":89,"interventions":91},"NCT00828230","Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis","TERMINATED",[56],"2011-08","2011-10","2008-09",17,[90],"Radiation Proctitis",[92],"budesonide",{"trials":94,"activeCount":195,"soonestReadout":41},[95,106,117,128,139,149,158,168,176,186],{"nctId":96,"briefTitle":97,"status":73,"phases":98,"primaryCompletion":99,"completion":99,"start":100,"enrollment":101,"conditions":102,"interventions":104},"NCT01209208","Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis",[57],"2017-06","2010-05",57,[103],"Lymphocytic Colitis",[42,105],"Mesalamine",{"nctId":107,"briefTitle":108,"status":73,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"NCT00838214","Budesonide 3x3mg\u002Fd Versus Prednisone in Active Autoimmune Hepatitis",[56,57],"2008-12","2001-03",208,[114],"Autoimmune Hepatitis",[92,116],"prednisone",{"nctId":118,"briefTitle":119,"status":73,"phases":120,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":126},"NCT00747110","Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)",[57],"2008-08","2010-08","2007-10",343,[20],[92,127],"mesalazine",{"nctId":129,"briefTitle":130,"status":73,"phases":131,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":138},"NCT01278082","SOIBD Collagenous Colitis Maintenance Study",[57],"2013-03","2013-09","2008-04",92,[137],"Induction and Maintaining Remission of Collagenous Colitis",[42],{"nctId":140,"briefTitle":141,"status":73,"phases":142,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":148},"NCT01086553","9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease",[57],"2012-05","2012-12","2009-11",471,[24],[92,92],{"nctId":150,"briefTitle":151,"status":73,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":157},"NCT00300118","Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)",[57],"2008-05","2004-09",311,[27],[92,127],{"nctId":159,"briefTitle":160,"status":83,"phases":161,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":166},"NCT00746486","Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)",[57],"2019-10","2009-02",62,[29],[92,167],"budesonide placebo",{"nctId":39,"briefTitle":40,"status":169,"phases":170,"primaryCompletion":41,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":175},"RECRUITING",[57],"2027-03","2021-05-21",308,[14],[42],{"nctId":177,"briefTitle":178,"status":73,"phases":179,"primaryCompletion":180,"completion":85,"start":181,"enrollment":135,"conditions":182,"interventions":184},"NCT00450086","Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis",[57],"2011-06","2007-03",[183],"Collagenous Colitis",[42,185],"Mesalazine",{"nctId":187,"briefTitle":188,"status":73,"phases":189,"primaryCompletion":76,"completion":76,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT00887263","Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)",[57],"2009-03",186,[193],"Oral Chronic Graft vs Host Disease",[42],1,{"trials":197,"activeCount":11},[],{"trials":199,"activeCount":11},[],{"intervention":201,"totalTrials":25,"cells":202},"norUrsodeoxycholic acid",{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":220,"PHASE4":230,"NA":232},{"trials":204,"activeCount":11},[],{"trials":206,"activeCount":11},[],{"trials":208,"activeCount":11},[209],{"nctId":210,"briefTitle":211,"status":212,"phases":213,"primaryCompletion":36,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":219},"NCT05083390","Norursodeoxycholic Acid vs. Placebo in NASH","UNKNOWN",[56],"2025-04","2019-07-08",363,[218],"Nonalcoholic Steatohepatitis",[201],{"trials":221,"activeCount":195,"soonestReadout":36},[222],{"nctId":34,"briefTitle":35,"status":223,"phases":224,"primaryCompletion":36,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":229},"ACTIVE_NOT_RECRUITING",[57],"2026-06","2018-02-08",303,[17],[37],{"trials":231,"activeCount":11},[],{"trials":233,"activeCount":11},[],{"intervention":52,"totalTrials":195,"cells":235},{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":251,"NA":253},{"trials":237,"activeCount":11},[],{"trials":239,"activeCount":11},[],{"trials":241,"activeCount":11},[],{"trials":243,"activeCount":195,"soonestReadout":51},[244],{"nctId":49,"briefTitle":50,"status":245,"phases":246,"primaryCompletion":51,"completion":51,"start":247,"enrollment":248,"conditions":249,"interventions":250},"NOT_YET_RECRUITING",[57],"2025-03",120,[17],[52],{"trials":252,"activeCount":11},[],{"trials":254,"activeCount":11},[],{"intervention":47,"totalTrials":195,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":270,"PHASE4":272,"NA":274},{"trials":258,"activeCount":11},[],{"trials":260,"activeCount":11},[],{"trials":262,"activeCount":195,"soonestReadout":46},[263],{"nctId":44,"briefTitle":45,"status":169,"phases":264,"primaryCompletion":46,"completion":46,"start":265,"enrollment":266,"conditions":267,"interventions":269},[56],"2024-06-10",356,[268],"Celiac Disease",[47],{"trials":271,"activeCount":11},[],{"trials":273,"activeCount":11},[],{"trials":275,"activeCount":11},[],{"intervention":277,"totalTrials":25,"cells":278},"UDCA",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":291,"PHASE3":293,"PHASE4":295,"NA":306},{"trials":280,"activeCount":11},[],{"trials":282,"activeCount":11},[283],{"nctId":284,"briefTitle":285,"status":73,"phases":286,"start":287,"conditions":288,"interventions":290},"NCT00529009","Pharmacokinetic Investigation of UDCA in Bile and Serum",[55],"2007-05",[289],"Healthy",[277],{"trials":292,"activeCount":11},[],{"trials":294,"activeCount":11},[],{"trials":296,"activeCount":11},[297],{"nctId":298,"briefTitle":299,"status":73,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":305},"NCT01510860","Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis",[58],"2010-07","2008-11",65,[29],[277,277],{"trials":307,"activeCount":11},[],{"intervention":185,"totalTrials":309,"cells":310},7,{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":371,"NA":373},{"trials":312,"activeCount":11},[],{"trials":314,"activeCount":11},[],{"trials":316,"activeCount":11},[],{"trials":318,"activeCount":11},[319,323,327,339,349,353,362],{"nctId":118,"briefTitle":119,"status":73,"phases":320,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":321,"interventions":322},[57],[20],[92,127],{"nctId":150,"briefTitle":151,"status":73,"phases":324,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":325,"interventions":326},[57],[27],[92,127],{"nctId":328,"briefTitle":329,"status":73,"phases":330,"primaryCompletion":287,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":335},"NCT00946946","Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine",[57],"2009-07","2002-02",78,[27],[336,185,337,338],"Azathioprine","Azathioprine placebo","Mesalazine placebo",{"nctId":340,"briefTitle":341,"status":83,"phases":342,"primaryCompletion":343,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":348},"NCT00695643","Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis",[57],"2011-11","2012-01","2008-01",345,[31],[185],{"nctId":177,"briefTitle":178,"status":73,"phases":350,"primaryCompletion":180,"completion":85,"start":181,"enrollment":135,"conditions":351,"interventions":352},[57],[183],[42,185],{"nctId":354,"briefTitle":355,"status":83,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":361},"NCT01038739","Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis",[57],"2013-01","2010-01",330,[31],[185,185],{"nctId":363,"briefTitle":364,"status":73,"phases":365,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":370},"NCT00449722","OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis",[57],"2006-06","2005-07",380,[22],[127],{"trials":372,"activeCount":11},[],{"trials":374,"activeCount":11},[],{"intervention":105,"totalTrials":18,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":394,"PHASE4":410,"NA":412},{"trials":378,"activeCount":11},[],{"trials":380,"activeCount":11},[],{"trials":382,"activeCount":11},[383],{"nctId":384,"briefTitle":385,"status":73,"phases":386,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":393},"NCT01627262","Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study",[56],"2004-08","2006-04","2002-05",123,[392],"Colonic Diverticulosis",[105],{"trials":395,"activeCount":11},[396,400],{"nctId":96,"briefTitle":97,"status":73,"phases":397,"primaryCompletion":99,"completion":99,"start":100,"enrollment":101,"conditions":398,"interventions":399},[57],[103],[42,105],{"nctId":401,"briefTitle":402,"status":73,"phases":403,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":408},"NCT02280629","Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)",[57],"2018-10-05","2014-10-01",150,[22],[409,105],"LT-02",{"trials":411,"activeCount":11},[],{"trials":413,"activeCount":11},[],{"intervention":415,"totalTrials":25,"cells":416},"Budesonide 1mg orodispersible tablet twice daily",{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":446,"NA":448},{"trials":418,"activeCount":11},[],{"trials":420,"activeCount":11},[],{"trials":422,"activeCount":11},[],{"trials":424,"activeCount":11},[425,435],{"nctId":426,"briefTitle":427,"status":73,"phases":428,"primaryCompletion":429,"completion":430,"start":431,"enrollment":432,"conditions":433,"interventions":434},"NCT02434029","Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis",[57],"2016-08-04","2016-10-04","2015-11-11",88,[14],[415],{"nctId":436,"briefTitle":437,"status":73,"phases":438,"primaryCompletion":439,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":444},"NCT02493335","Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis",[57],"2018-11-28","2020-12-11","2016-01-15",204,[14],[445,415],"Budesonide 0.5mg orodispersible tablet twice daily",{"trials":447,"activeCount":11},[],{"trials":449,"activeCount":11},[],{"intervention":409,"totalTrials":25,"cells":451},{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":474,"NA":476},{"trials":453,"activeCount":11},[],{"trials":455,"activeCount":11},[],{"trials":457,"activeCount":11},[],{"trials":459,"activeCount":11},[460,464],{"nctId":401,"briefTitle":402,"status":73,"phases":461,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":462,"interventions":463},[57],[22],[409,105],{"nctId":465,"briefTitle":466,"status":83,"phases":467,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":473},"NCT02142725","Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis",[57],"2016-11-11","2016-12-16","2014-07-21",468,[22],[409,409],{"trials":475,"activeCount":11},[],{"trials":477,"activeCount":11},[],{"intervention":445,"totalTrials":195,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":492,"NA":494},{"trials":481,"activeCount":11},[],{"trials":483,"activeCount":11},[],{"trials":485,"activeCount":11},[],{"trials":487,"activeCount":11},[488],{"nctId":436,"briefTitle":437,"status":73,"phases":489,"primaryCompletion":439,"completion":440,"start":441,"enrollment":442,"conditions":490,"interventions":491},[57],[14],[445,415],{"trials":493,"activeCount":11},[],{"trials":495,"activeCount":11},[],{"intervention":116,"totalTrials":195,"cells":497},{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":510,"NA":512},{"trials":499,"activeCount":11},[],{"trials":501,"activeCount":11},[],{"trials":503,"activeCount":11},[],{"trials":505,"activeCount":11},[506],{"nctId":107,"briefTitle":108,"status":73,"phases":507,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":508,"interventions":509},[56,57],[114],[92,116],{"trials":511,"activeCount":11},[],{"trials":513,"activeCount":11},[],{"intervention":515,"totalTrials":195,"cells":516},"Mesalazine - TID 1000 mg",{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":536,"NA":538},{"trials":518,"activeCount":11},[],{"trials":520,"activeCount":11},[],{"trials":522,"activeCount":11},[],{"trials":524,"activeCount":11},[525],{"nctId":526,"briefTitle":527,"status":73,"phases":528,"primaryCompletion":529,"completion":530,"start":357,"enrollment":531,"conditions":532,"interventions":534},"NCT01745770","TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)",[57],"2015-03","2015-06",306,[533],"Active Ulcerative Colitis",[515,535],"Mesalazine - TID 2x 500 mg",{"trials":537,"activeCount":11},[],{"trials":539,"activeCount":11},[],{"intervention":535,"totalTrials":195,"cells":541},{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":554,"NA":556},{"trials":543,"activeCount":11},[],{"trials":545,"activeCount":11},[],{"trials":547,"activeCount":11},[],{"trials":549,"activeCount":11},[550],{"nctId":526,"briefTitle":527,"status":73,"phases":551,"primaryCompletion":529,"completion":530,"start":357,"enrollment":531,"conditions":552,"interventions":553},[57],[533],[515,535],{"trials":555,"activeCount":11},[],{"trials":557,"activeCount":11},[],{"intervention":559,"totalTrials":195,"cells":560},"Rifamycin SV-MMX®",{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":567,"PHASE4":581,"NA":583},{"trials":562,"activeCount":11},[],{"trials":564,"activeCount":11},[],{"trials":566,"activeCount":11},[],{"trials":568,"activeCount":11},[569],{"nctId":570,"briefTitle":571,"status":73,"phases":572,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":579},"NCT01208922","Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea",[57],"2016-01","2016-05","2010-11",835,[578],"Traveler's Diarrhea",[559,580],"Ciprofloxacin",{"trials":582,"activeCount":11},[],{"trials":584,"activeCount":11},[],{"intervention":580,"totalTrials":195,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":593,"PHASE4":599,"NA":601},{"trials":588,"activeCount":11},[],{"trials":590,"activeCount":11},[],{"trials":592,"activeCount":11},[],{"trials":594,"activeCount":11},[595],{"nctId":570,"briefTitle":571,"status":73,"phases":596,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":597,"interventions":598},[57],[578],[559,580],{"trials":600,"activeCount":11},[],{"trials":602,"activeCount":11},[],{"intervention":167,"totalTrials":195,"cells":604},{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":617,"NA":619},{"trials":606,"activeCount":11},[],{"trials":608,"activeCount":11},[],{"trials":610,"activeCount":11},[],{"trials":612,"activeCount":11},[613],{"nctId":159,"briefTitle":160,"status":83,"phases":614,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":615,"interventions":616},[57],[29],[92,167],{"trials":618,"activeCount":11},[],{"trials":620,"activeCount":11},[],{"intervention":336,"totalTrials":195,"cells":622},{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":629,"PHASE4":635,"NA":637},{"trials":624,"activeCount":11},[],{"trials":626,"activeCount":11},[],{"trials":628,"activeCount":11},[],{"trials":630,"activeCount":11},[631],{"nctId":328,"briefTitle":329,"status":73,"phases":632,"primaryCompletion":287,"completion":331,"start":332,"enrollment":333,"conditions":633,"interventions":634},[57],[27],[336,185,337,338],{"trials":636,"activeCount":11},[],{"trials":638,"activeCount":11},[],{"intervention":337,"totalTrials":195,"cells":640},{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":647,"PHASE4":653,"NA":655},{"trials":642,"activeCount":11},[],{"trials":644,"activeCount":11},[],{"trials":646,"activeCount":11},[],{"trials":648,"activeCount":11},[649],{"nctId":328,"briefTitle":329,"status":73,"phases":650,"primaryCompletion":287,"completion":331,"start":332,"enrollment":333,"conditions":651,"interventions":652},[57],[27],[336,185,337,338],{"trials":654,"activeCount":11},[],{"trials":656,"activeCount":11},[],{"intervention":338,"totalTrials":195,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":665,"PHASE4":671,"NA":673},{"trials":660,"activeCount":11},[],{"trials":662,"activeCount":11},[],{"trials":664,"activeCount":11},[],{"trials":666,"activeCount":11},[667],{"nctId":328,"briefTitle":329,"status":73,"phases":668,"primaryCompletion":287,"completion":331,"start":332,"enrollment":333,"conditions":669,"interventions":670},[57],[27],[336,185,337,338],{"trials":672,"activeCount":11},[],{"trials":674,"activeCount":11},[],{"intervention":676,"totalTrials":195,"cells":677},"Budesonide granules 9 mg",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":696,"NA":698},{"trials":679,"activeCount":11},[],{"trials":681,"activeCount":11},[],{"trials":683,"activeCount":11},[],{"trials":685,"activeCount":11},[686],{"nctId":687,"briefTitle":688,"status":73,"phases":689,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":695},"NCT02142634","Budesonide for Induction of Remission in Incomplete Microscopic Colitis",[57],"2020-02","2014-05",44,[694],"Incomplete Microscopic Colitis",[676],{"trials":697,"activeCount":11},[],{"trials":699,"activeCount":11},[],{"intervention":701,"totalTrials":195,"cells":702},"mesalamine granules",{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":722,"NA":724},{"trials":704,"activeCount":11},[],{"trials":706,"activeCount":11},[],{"trials":708,"activeCount":11},[],{"trials":710,"activeCount":11},[711],{"nctId":712,"briefTitle":713,"status":73,"phases":714,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":721},"NCT00746447","Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)",[57],"2007-04","2008-03","2005-05",648,[20,720],"Recurrence",[701,701,701],{"trials":723,"activeCount":11},[],{"trials":725,"activeCount":11},[],{"intervention":727,"totalTrials":195,"cells":728},"norUDCA",{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":743,"PHASE4":745,"NA":747},{"trials":730,"activeCount":11},[],{"trials":732,"activeCount":11},[],{"trials":734,"activeCount":11},[735],{"nctId":736,"briefTitle":737,"status":73,"phases":738,"primaryCompletion":76,"completion":739,"start":144,"enrollment":740,"conditions":741,"interventions":742},"NCT01755507","Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis",[56],"2015-12",159,[17],[727],{"trials":744,"activeCount":11},[],{"trials":746,"activeCount":11},[],{"trials":748,"activeCount":11},[],{"intervention":750,"totalTrials":195,"cells":751},"Mesalamine Oral Product",{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":767,"PHASE4":769,"NA":771},{"trials":753,"activeCount":11},[],{"trials":755,"activeCount":11},[],{"trials":757,"activeCount":11},[758],{"nctId":759,"briefTitle":760,"status":73,"phases":761,"primaryCompletion":762,"completion":763,"start":764,"enrollment":15,"conditions":765,"interventions":766},"NCT05488405","Mesalazine Oral Suspension in Active Eosinophilic Esophagitis",[56],"2023-06-30","2023-07-20","2023-02-09",[14],[750],{"trials":768,"activeCount":11},[],{"trials":770,"activeCount":11},[],{"trials":772,"activeCount":11},[],{"intervention":774,"totalTrials":195,"cells":775},"Budesonide 2 mg suppository",{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":780,"PHASE3":794,"PHASE4":796,"NA":798},{"trials":777,"activeCount":11},[],{"trials":779,"activeCount":11},[],{"trials":781,"activeCount":11},[782],{"nctId":783,"briefTitle":784,"status":73,"phases":785,"primaryCompletion":786,"completion":786,"start":133,"enrollment":787,"conditions":788,"interventions":790},"NCT01966783","Budesonide vs. Mesalazine vs. Budesonide\u002FMesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis",[56],"2015-08",320,[789],"Proctitis",[774,791,792,793],"Budesonide 4 mg suppository","Mesalazine 1 g suppository","Budesonide 2 mg suppository\u002FMesalazine 1 g suppository",{"trials":795,"activeCount":11},[],{"trials":797,"activeCount":11},[],{"trials":799,"activeCount":11},[],{"intervention":791,"totalTrials":195,"cells":801},{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":812,"PHASE4":814,"NA":816},{"trials":803,"activeCount":11},[],{"trials":805,"activeCount":11},[],{"trials":807,"activeCount":11},[808],{"nctId":783,"briefTitle":784,"status":73,"phases":809,"primaryCompletion":786,"completion":786,"start":133,"enrollment":787,"conditions":810,"interventions":811},[56],[789],[774,791,792,793],{"trials":813,"activeCount":11},[],{"trials":815,"activeCount":11},[],{"trials":817,"activeCount":11},[],{"intervention":792,"totalTrials":195,"cells":819},{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":830,"PHASE4":832,"NA":834},{"trials":821,"activeCount":11},[],{"trials":823,"activeCount":11},[],{"trials":825,"activeCount":11},[826],{"nctId":783,"briefTitle":784,"status":73,"phases":827,"primaryCompletion":786,"completion":786,"start":133,"enrollment":787,"conditions":828,"interventions":829},[56],[789],[774,791,792,793],{"trials":831,"activeCount":11},[],{"trials":833,"activeCount":11},[],{"trials":835,"activeCount":11},[],{"intervention":793,"totalTrials":195,"cells":837},{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":848,"PHASE4":850,"NA":852},{"trials":839,"activeCount":11},[],{"trials":841,"activeCount":11},[],{"trials":843,"activeCount":11},[844],{"nctId":783,"briefTitle":784,"status":73,"phases":845,"primaryCompletion":786,"completion":786,"start":133,"enrollment":787,"conditions":846,"interventions":847},[56],[789],[774,791,792,793],{"trials":849,"activeCount":11},[],{"trials":851,"activeCount":11},[],{"trials":853,"activeCount":11},[],{"intervention":855,"totalTrials":195,"cells":856},"ZED1227",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":874,"PHASE4":876,"NA":878},{"trials":858,"activeCount":11},[],{"trials":860,"activeCount":11},[],{"trials":862,"activeCount":11},[863],{"nctId":864,"briefTitle":865,"status":73,"phases":866,"primaryCompletion":867,"completion":868,"start":869,"enrollment":191,"conditions":870,"interventions":873},"NCT05305599","Different Doses of ZED1227 vs. Placebo in NAFLD",[56],"2023-06-07","2023-07-05","2022-04-19",[871,872],"NAFLD","Liver Fibrosis",[855],{"trials":875,"activeCount":11},[],{"trials":877,"activeCount":11},[],{"trials":879,"activeCount":11},[],{"intervention":881,"totalTrials":195,"cells":882},"low dose budesonide",{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":899,"PHASE4":901,"NA":903},{"trials":884,"activeCount":11},[],{"trials":886,"activeCount":11},[],{"trials":888,"activeCount":11},[889],{"nctId":890,"briefTitle":891,"status":73,"phases":892,"primaryCompletion":893,"completion":691,"start":180,"enrollment":894,"conditions":895,"interventions":896},"NCT02280616","Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis",[56],"2013-04",76,[14],[881,897,898],"high dose budesonide","high dose budesonide suspension",{"trials":900,"activeCount":11},[],{"trials":902,"activeCount":11},[],{"trials":904,"activeCount":11},[],{"intervention":897,"totalTrials":195,"cells":906},{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":908,"activeCount":11},[],{"trials":910,"activeCount":11},[],{"trials":912,"activeCount":11},[913],{"nctId":890,"briefTitle":891,"status":73,"phases":914,"primaryCompletion":893,"completion":691,"start":180,"enrollment":894,"conditions":915,"interventions":916},[56],[14],[881,897,898],{"trials":918,"activeCount":11},[],{"trials":920,"activeCount":11},[],{"trials":922,"activeCount":11},[],{"intervention":898,"totalTrials":195,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":926,"activeCount":11},[],{"trials":928,"activeCount":11},[],{"trials":930,"activeCount":11},[931],{"nctId":890,"briefTitle":891,"status":73,"phases":932,"primaryCompletion":893,"completion":691,"start":180,"enrollment":894,"conditions":933,"interventions":934},[56],[14],[881,897,898],{"trials":936,"activeCount":11},[],{"trials":938,"activeCount":11},[],{"trials":940,"activeCount":11},[],{"intervention":942,"totalTrials":195,"cells":943},"Rifamycin SV-MMX® 400 mg b.i.d.",{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":961,"PHASE4":963,"NA":965},{"trials":945,"activeCount":11},[],{"trials":947,"activeCount":11},[],{"trials":949,"activeCount":11},[950],{"nctId":951,"briefTitle":952,"status":73,"phases":953,"primaryCompletion":954,"completion":954,"start":955,"enrollment":442,"conditions":956,"interventions":958},"NCT01847664","Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis",[56],"2017-07","2013-08",[957],"Uncomplicated Diverticulitis",[942,959,960],"Rifamycin SV-MMX® 600 mg t.i.d.","Rifamycin SV-MMX® Placebo",{"trials":962,"activeCount":11},[],{"trials":964,"activeCount":11},[],{"trials":966,"activeCount":11},[],{"intervention":959,"totalTrials":195,"cells":968},{"EARLY_PHASE1":969,"PHASE1":971,"PHASE2":973,"PHASE3":979,"PHASE4":981,"NA":983},{"trials":970,"activeCount":11},[],{"trials":972,"activeCount":11},[],{"trials":974,"activeCount":11},[975],{"nctId":951,"briefTitle":952,"status":73,"phases":976,"primaryCompletion":954,"completion":954,"start":955,"enrollment":442,"conditions":977,"interventions":978},[56],[957],[942,959,960],{"trials":980,"activeCount":11},[],{"trials":982,"activeCount":11},[],{"trials":984,"activeCount":11},[],{"intervention":960,"totalTrials":195,"cells":986},{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":997,"PHASE4":999,"NA":1001},{"trials":988,"activeCount":11},[],{"trials":990,"activeCount":11},[],{"trials":992,"activeCount":11},[993],{"nctId":951,"briefTitle":952,"status":73,"phases":994,"primaryCompletion":954,"completion":954,"start":955,"enrollment":442,"conditions":995,"interventions":996},[56],[957],[942,959,960],{"trials":998,"activeCount":11},[],{"trials":1000,"activeCount":11},[],{"trials":1002,"activeCount":11},[],{"intervention":1004,"totalTrials":195,"cells":1005},"Low dose TSO",{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1007,"activeCount":11},[],{"trials":1009,"activeCount":11},[],{"trials":1011,"activeCount":11},[1012],{"nctId":1013,"briefTitle":1014,"status":73,"phases":1015,"primaryCompletion":1016,"completion":1016,"start":575,"enrollment":1017,"conditions":1018,"interventions":1019},"NCT01279577","Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease",[56],"2014-02",254,[24],[1004,1020,1021],"Medium dose TSO","High dose TSO",{"trials":1023,"activeCount":11},[],{"trials":1025,"activeCount":11},[],{"trials":1027,"activeCount":11},[],{"intervention":1020,"totalTrials":195,"cells":1029},{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1040,"PHASE4":1042,"NA":1044},{"trials":1031,"activeCount":11},[],{"trials":1033,"activeCount":11},[],{"trials":1035,"activeCount":11},[1036],{"nctId":1013,"briefTitle":1014,"status":73,"phases":1037,"primaryCompletion":1016,"completion":1016,"start":575,"enrollment":1017,"conditions":1038,"interventions":1039},[56],[24],[1004,1020,1021],{"trials":1041,"activeCount":11},[],{"trials":1043,"activeCount":11},[],{"trials":1045,"activeCount":11},[],{"intervention":1021,"totalTrials":195,"cells":1047},{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1058,"PHASE4":1060,"NA":1062},{"trials":1049,"activeCount":11},[],{"trials":1051,"activeCount":11},[],{"trials":1053,"activeCount":11},[1054],{"nctId":1013,"briefTitle":1014,"status":73,"phases":1055,"primaryCompletion":1016,"completion":1016,"start":575,"enrollment":1017,"conditions":1056,"interventions":1057},[56],[24],[1004,1020,1021],{"trials":1059,"activeCount":11},[],{"trials":1061,"activeCount":11},[],{"trials":1063,"activeCount":11},[],{"intervention":1065,"totalTrials":195,"cells":1066},"Naronapride",{"EARLY_PHASE1":1067,"PHASE1":1069,"PHASE2":1071,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1068,"activeCount":11},[],{"trials":1070,"activeCount":11},[],{"trials":1072,"activeCount":11},[1073],{"nctId":1074,"briefTitle":1075,"status":73,"phases":1076,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1083},"NCT05621811","Different Doses of Naronapride vs. Placebo in Gastroparesis",[56],"2025-08-12","2025-09-04","2023-01-03",328,[1082],"Gastroparesis",[1065],{"trials":1085,"activeCount":11},[],{"trials":1087,"activeCount":11},[],{"trials":1089,"activeCount":11},[]]